• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment.

作者信息

Longo Miriam, Maiorino Maria Ida, Giugliano Dario, Knop Filip K, Esposito Katherine

机构信息

Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.

Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

出版信息

Endocrine. 2025 Apr 24. doi: 10.1007/s12020-025-04243-6.

DOI:10.1007/s12020-025-04243-6
PMID:40274685
Abstract
摘要

相似文献

1
Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment.胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例联合用药：简化2型糖尿病治疗
Endocrine. 2025 Apr 24. doi: 10.1007/s12020-025-04243-6.
2
Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies.基于德尔菲法对基础胰岛素联合口服治疗失败的2型糖尿病患者强化治疗的共识：聚焦基础胰岛素+胰高血糖素样肽-1受体激动剂联合疗法
Diabetes Ther. 2021 Mar;12(3):781-800. doi: 10.1007/s13300-021-01012-2. Epub 2021 Feb 7.
3
Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.胰岛素甘精/利西拉来固定比例复方制剂（iGlarLixi）改善 2 型糖尿病患者的 β 细胞功能。
Diabetes Obes Metab. 2022 Jun;24(6):1159-1165. doi: 10.1111/dom.14688. Epub 2022 Mar 28.
4
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.基础胰岛素/胰高血糖素样肽-1受体激动剂固定比例复方制剂（德谷胰岛素利拉鲁肽和甘精胰岛素利司那肽）用于2型糖尿病管理的理论依据、起始治疗及滴定方法
Diabetes Ther. 2017 Aug;8(4):739-752. doi: 10.1007/s13300-017-0287-y. Epub 2017 Jul 18.
5
Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.基础胰岛素与胰高血糖素样肽-1受体激动剂固定比例联合治疗2型糖尿病：文献要点
Endocr Metab Immune Disord Drug Targets. 2021;21(4):626-646. doi: 10.2174/1871530320666200705211224.
6
Predictors of Use of Individual Insulin and GLP-1 RA Products Versus Fixed Ratio Insulin/GLP-1 RA Combinations in Medicare Beneficiaries.医疗保险受益人中使用单一胰岛素和胰高血糖素样肽-1受体激动剂（GLP-1 RA）产品与固定比例胰岛素/GLP-1 RA组合的预测因素
Sr Care Pharm. 2025 Feb 1;40(2):97-104. doi: 10.4140/TCP.n.2025.97.
7
Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison.基础胰岛素与 GLP-1 受体激动剂的固定比例与自由联合治疗 GLP-1 受体激动剂控制不佳的 2 型糖尿病：系统评价和间接治疗比较。
Front Endocrinol (Lausanne). 2022 May 20;13:870722. doi: 10.3389/fendo.2022.870722. eCollection 2022.
8
Comparation of fixed-ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon-like peptide-1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta-analysis.固定比例（IDegLira 和 iGlarLixi）与基础胰岛素和胰高血糖素样肽-1 受体激动剂联合治疗未控制 2 型糖尿病的比较：系统评价和网络荟萃分析。
J Evid Based Med. 2024 Jun;17(2):370-376. doi: 10.1111/jebm.12620. Epub 2024 Jun 10.
9
Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.既往接受注射治疗的2型糖尿病患者起始使用固定复方制剂德谷胰岛素利拉鲁肽：来自法国EASY真实世界研究的见解
Diabetes Ther. 2022 Dec;13(11-12):1947-1963. doi: 10.1007/s13300-022-01327-8. Epub 2022 Nov 4.
10
Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.2 型糖尿病患者中使用门冬胰岛素 30/70 与 GLP-1 受体激动剂双联治疗与第一代基础胰岛素与 GLP-1 受体激动剂三联治疗的真实世界研究。
Diabet Med. 2024 May;41(5):e15267. doi: 10.1111/dme.15267. Epub 2023 Dec 13.

引用本文的文献

1
BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.4年以上：使用基础胰岛素与胰高血糖素样肽-1受体激动剂的固定比例组合或基础胰岛素与钠-葡萄糖协同转运蛋白2抑制剂的固定比例组合简化复杂胰岛素治疗方案。
Diabetologia. 2025 Aug 28. doi: 10.1007/s00125-025-06535-y.

本文引用的文献

1
Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus.每周一次固定剂量复方胰岛素伊克德与司美格鲁肽与单独使用各成分在 2 型糖尿病患者中的药代动力学特性比较。
Clin Drug Investig. 2024 Nov;44(11):849-861. doi: 10.1007/s40261-024-01405-8. Epub 2024 Nov 3.
2
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.胰高血糖素样肽-1 受体：作用机制与治疗进展。
Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z.
3
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.
在未接受过胰岛素治疗的2型糖尿病患者中，胰岛素艾塞那肽与德谷胰岛素的对比研究
N Engl J Med. 2024 Dec 12;391(23):2201-2211. doi: 10.1056/NEJMoa2403953. Epub 2024 Sep 10.
4
Effect of fixed-ratio insulin combinations on adherence in type 2 diabetes: Systematic review.固定剂量胰岛素组合对 2 型糖尿病患者依从性的影响：系统评价。
Diabetes Metab Syndr. 2024 Jun;18(6):103072. doi: 10.1016/j.dsx.2024.103072. Epub 2024 Jul 11.
5
Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes.一周一次胰岛素：减轻糖尿病患者治疗负担的有前途方法。
Diabetologia. 2024 Aug;67(8):1480-1492. doi: 10.1007/s00125-024-06158-9. Epub 2024 Apr 29.
6
BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.2 年以上：通过简化复杂的 2 型糖尿病胰岛素方案，实现代谢益处的持久性。
Endocrine. 2024 Feb;83(2):399-404. doi: 10.1007/s12020-023-03547-9. Epub 2023 Oct 3.
7
IDegLira for type 2 diabetes: a systematic review and meta-analysis.德谷胰岛素治疗 2 型糖尿病：系统评价和荟萃分析。
Endocrine. 2024 Mar;83(3):648-658. doi: 10.1007/s12020-023-03543-z. Epub 2023 Sep 28.
8
Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects.钠-葡萄糖协同转运蛋白2抑制剂的临床益处及其心血管效应的潜在机制。
JACC Asia. 2022 Jun 7;2(3):287-293. doi: 10.1016/j.jacasi.2022.03.009. eCollection 2022 Jun.
9
Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study.既往接受注射治疗的2型糖尿病患者起始使用固定复方制剂德谷胰岛素利拉鲁肽：来自法国EASY真实世界研究的见解
Diabetes Ther. 2022 Dec;13(11-12):1947-1963. doi: 10.1007/s13300-022-01327-8. Epub 2022 Nov 4.
10
Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes.专家小组关于简化复杂胰岛素治疗方案以改善2型糖尿病治疗效果的指南及叙述性综述
Diabetes Ther. 2022 Apr;13(4):619-634. doi: 10.1007/s13300-022-01222-2. Epub 2022 Mar 11.